Notice of Class Action Lawsuit for Embecta Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, to apply as lead plaintiffs by August 17, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Embecta made false or misleading statements regarding its financial results, leading to investor losses when the company failed to meet expectations and cut its 2026 fiscal guidance, highlighting significant management failures.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EMBC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EMBC
About EMBC
Embecta Corp. is a global medical device company. It provides solutions to improve the health and well-being of people living with diabetes. Its portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through channels, including retail, hospitals and pharmacies. It is also a manufacturer of medical devices and drug delivery technologies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

- Lawsuit Background: Embecta Corp. is facing a securities class action lawsuit due to its disastrous Q2 2026 earnings report, with the class period spanning from November 25, 2025, to May 4, 2026, reflecting severe investor disappointment regarding the company's future outlook.
- Deteriorating Financial Performance: The company reported an adjusted EPS of only $0.27 for Q2 2026, representing a staggering 61% decline both sequentially and year-over-year, starkly contrasting with prior assurances of stability, leading to a significant drop in stock price.
- Guidance Downgrade: Embecta slashed its 2026 adjusted EPS guidance to $1.55 - $1.75, a reduction of approximately 43% at the midpoint, while also cutting its dividend by 93% to just $0.01, exacerbating market concerns about its financial health.
- Investor Confidence Erosion: Analysts highlighted the need for Embecta's management to rebuild investor credibility regarding commercial execution and profitability outlook, indicating significant deficiencies in the company's transparency and risk management practices.
See More
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Embecta for investors who purchased shares between November 25, 2025, and May 4, 2026, with a deadline of August 17, 2026, to apply as lead plaintiffs.
- False Statements Allegations: The complaint alleges that Embecta misled investors by providing overly positive financial guidance while concealing adverse facts about its fiscal health, particularly regarding poor performance in its pen needle product line.
- Stock Price Plunge: Following the release of disappointing second-quarter earnings on May 5, 2026, Embecta's stock price plummeted from $9.25 to $3.90 per share, a decline of approximately 58%, indicating severe market concerns about the company's financial stability.
- Cost Structure Review: The company announced a review of its cost structure and organizational footprint, reflecting the operational pressures and strategic adjustments needed in light of market softness and high customer concentration.
See More
- Stock Price Collapse: Embecta Corp. experienced a staggering 57.8% drop in share price on May 5, 2026, plummeting from $9.25 to $3.90, primarily due to the company disclosing a revenue shortfall exceeding $75 million and drastically cutting its fiscal year 2026 guidance, which severely undermined investor confidence.
- Lead Plaintiff Application Deadline: Investors must file a motion for lead plaintiff status by August 17, 2026, with eligibility requiring the purchase of EMBC securities between November 25, 2025, and May 4, 2026, ensuring that those with significant financial interests can adequately represent the class.
- Class Action Procedures: Following the deadline, the court will review all lead plaintiff motions and appoint a lead plaintiff within 60 to 90 days, who will then select lead counsel to prosecute the action on behalf of all class members, ensuring effective case management.
- Investor Rights Protection: Investors who do not seek lead plaintiff status remain automatic class members and do not need to take any action before the deadline to preserve their rights to future recovery, thereby safeguarding the interests of all affected investors.
See More
- Lawsuit Background: Bleichmar Fonti & Auld LLP has announced a class action lawsuit against Embecta Corp and its executives for securities fraud, resulting in a significant stock drop that severely undermines investor confidence in the company's future prospects.
- Stock Price Plunge: On May 5, 2026, Embecta's Q2 results fell short of expectations, causing its stock price to plummet from $9.25 to $3.90, a staggering 57.8% drop, which not only erodes investor value but may also complicate the company's future financing efforts.
- Competitive Market Pressure: The lawsuit highlights that Embecta's insulin pen product line, previously touted as strong, is actually facing significant competition and overall market softness, indicating a misalignment in the company's market strategy and execution.
- Dividend Cut: Due to disappointing performance, Embecta slashed its quarterly dividend from $0.15 to $0.01, reflecting cash flow challenges that could hinder future investments and growth plans, further eroding investor confidence.
See More
- Lawsuit Background: Embecta Corp. is facing a securities class action lawsuit following its disastrous Q2 2026 earnings report, which has raised significant concerns about the company's credibility among investors who purchased shares between November 25, 2025, and May 4, 2026.
- Performance Decline: The company reported an adjusted EPS of only $0.27 for Q2 2026, representing a staggering 61% year-over-year decline, starkly contrasting with its previous guidance of $2.80 to $3.00 for the year, leading to a substantial loss of investor confidence.
- Dividend Cut: Embecta slashed its 2026 adjusted EPS guidance to $1.55 to $1.75 and reduced its dividend by 93% to just $0.01, highlighting severe challenges in its core pen needle market and the impact on shareholder returns.
- Market Reaction: The stock experienced a significant selloff as the management failed to adequately communicate potential risks, with analysts emphasizing the need for the company to rebuild investor trust in its commercial execution and profitability outlook, indicating uncertainty in its future growth prospects.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased common stock of Embecta Corp. between November 25, 2025, and May 4, 2026, to apply as lead plaintiff by August 17, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Embecta made false or misleading statements regarding its financial results, particularly in its 2026 fiscal guidance, leading to investor losses when the true situation was revealed, thereby impacting the company's market credibility.
- Law Firm Expertise: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record, urging investors to choose experienced legal counsel wisely.
- Investor Rights Protection: Until the class action is certified, investors can choose to remain absent or hire counsel, with their ability to share in any potential future recovery not dependent on serving as lead plaintiff, ensuring all investors have the opportunity to participate in potential compensation.
See More










